Getz Pharma registers community NCD screening study in Faisalabad, Pakistan
Getz Pharma listed a new observational trial screening for obesity, diabetes, hypertension, and dyslipidemia in suburban Faisalabad, not yet recruiting.
Getz Pharma's activity for the week centers on a single newly registered study addressing noncommunicable disease burden in Pakistan.
- "Faisalabad Initiative of Research and Management of NCDs" (FIRM-NCD, NCT07676214) is an observational study sponsored by Getz Pharma with Faisalabad Medical Center as collaborator, listed as not yet recruiting with an estimated start of 2026-08-01. The study aims to evaluate a community-based project focusing on disease awareness, screening, and structured referral to trained treating physicians for early diagnosis and management of major NCDs1, with a primary objective centered on measuring how common obesity, diabetes, hypertension, and dyslipidemia are among residents of suburban Faisalabad.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.